Paying users zone. Data is covered by .

  • Get to Eli Lilly & Co. for $15.99, or

  • get to whole website for at least 3 months from $49.99.

 

$15.99


Free Cash Flow to The Firm (FCFF)

Eli Lilly & Co., FCFF calculation

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Net income (loss)
Net noncash charges
Other changes in operating assets and liabilities, net of acquisitions and divestitures
Net cash provided by operating activities
Cash payments for interest on borrowings, net of tax1
Interest costs capitalized, net of tax2
Purchases of property and equipment
Disposals of property and equipment
Free cash flow to the firm (FCFF)
Item Description The company
FCFF Free cash flow to the firm is the cash flow available to the Eli Lilly & Co.'s suppliers of capital after all operating expenses have been paid and necessary investments in working and fixed capital have been made. Eli Lilly & Co.'s FCFF increased from 2015 to 2016 and from 2016 to 2017.

Top


Interest Paid, Net of Tax

Eli Lilly & Co., interest paid, net of tax calculation

USD $ in thousands

 
12 months ended Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Effective Income Tax Rate (EITR)
EITR1 % % % % %
Interest Paid, Net of Tax
Cash payments for interest on borrowings, before tax
Less: Cash payments for interest on borrowings, tax2
Cash payments for interest on borrowings, net of tax
Interest Costs Capitalized, Net of Tax
Interest costs capitalized, before tax
Less: Interest costs capitalized, tax3
Interest costs capitalized, net of tax

2017 Calculations

2 Cash payments for interest on borrowings, tax = Cash payments for interest on borrowings × EITR
= × % =

3 Interest costs capitalized, tax = Interest costs capitalized × EITR
= × % =

Top


Enterprise Value to FCFF Ratio, Current

Eli Lilly & Co., current EV/FCFF calculation, comparison to benchmarks

 
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)
Free cash flow to the firm (FCFF)
Ratio
EV/FCFF
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

If company EV/FCFF is lower then the EV/FCFF of benchmark then company is relatively undervalued.

Otherwise, if company EV/FCFF is higher then the EV/FCFF of benchmark then company is relatively overvalued.

Top


Enterprise Value to FCFF Ratio, Historical

Eli Lilly & Co., historical EV/FCFF calculation, comparison to benchmarks

 
Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)1
Free cash flow to the firm (FCFF)2
Ratio
EV/FCFF3
Benchmarks
EV/FCFF, Competitors
Abbott Laboratories
AbbVie Inc.
Allergan PLC
Amgen Inc.
Biogen Inc.
Bristol-Myers Squibb Co.
Celgene Corp.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
EV/FCFF, Sector
Pharmaceuticals & Biotechnology
EV/FCFF, Industry
Health Care

2017 Calculations

3 EV/FCFF = EV ÷ FCFF
= ÷ =

Ratio Description The company
EV/FCFF Enterprise value to free cash flow to the firm is whole company valuation indicator. Eli Lilly & Co.'s EV/FCFF ratio declined from 2015 to 2016 and from 2016 to 2017.

Top